menu
    • menu
    [{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"NM-102","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Gustave Roussy","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Gustave Roussy"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plakous Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cellspan Esophageal Implant","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Inapplicable"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ossium Health \/ Inapplicable"},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Funding","leadProduct":"Maltosyl-Isomaltooligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive \/ Virginia Catalyst"},{"orgOrder":0,"company":"Renexxion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renexxion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Renexxion \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MLL-Menin interaction","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MLL-Menin interaction","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Genson Capital"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Eventide Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Eventide Asset Management"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Xiling Lab \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MitoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tr1X Bio \/ Inapplicable"}]

    Find FDA Investigational New Drug (IND) Submissions for Gastroenterology

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurenati Therapeutics

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Neurenati Therapeutics

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan & Rare Pediatric Status to Neurenati’s NEU-001 for Hirschsprung

                            Details : NEU-001 is a first-in-class, once-in-a-lifetime treatment administered intrarectally, which is being evaluated to treat Hirschsprung's disease.

                            Product Name : NEU-001

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 04, 2025

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shattuck Labs

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Shattuck Labs

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shattuck Labs Shares Positive Data on SL-325 in IBD at ECCO 2025

                            Details : SL-325 is a first-in-class DR3 antagonist, currently being investigated for the treatment of inflammatory bowel diseases.

                            Product Name : SL-325

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kura Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Kura Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziftomenib,Imatinib Mesylate

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kura Preclinical Data Supports Ziftomenib for Gastrointestinal Tumors

                            Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                            Product Name : KO-539

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 24, 2024

                            Lead Product(s) : Ziftomenib,Imatinib Mesylate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kura Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Kura Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziftomenib,Imatinib Mesylate

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kura Oncology Receives FDA IND Clearance For Menin Inhibitor Ziftomenib in GIST

                            Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                            Product Name : KO-539

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 08, 2024

                            Lead Product(s) : Ziftomenib,Imatinib Mesylate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tr1X Bio

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Tr1X Bio

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRX103

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tr1X Announces FDA Clearance of IND Application for TRX103 for Refractory Crohn’s Disease

                            Details : TRX103, a first-in-class Type 1 Treg cell therapy candidate, which is being evaluated for the treatment of patients with treatment-refractory crohn’s disease.

                            Product Name : TRX103

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 08, 2024

                            Lead Product(s) : TRX103

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shattuck Labs

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Shattuck Labs

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shattuck Labs Announces SL-325, a First-In-Class DR3 Antagonist, in TL1A/DR3 Pathway

                            Details : SL-325 is a first-in-class antagonist antibody to DR3, the receptor for TL1A, which is being evaluated for the treatment of inflammatory bowel disease.

                            Product Name : SL-325

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 10, 2024

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Renexxion

                            Ireland arrow
                            German Wound Congress
                            Not Confirmed

                            Renexxion

                            Ireland arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naronapride

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of...

                            Details : Naronapride possess both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties. It is currently being investigaetd for chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD).

                            Product Name : ATI-7505

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 01, 2023

                            Lead Product(s) : Naronapride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            OnQuality Pharma

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            OnQuality Pharma

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OQL051

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OnQuality Announces FDA Clearance of IND Application for OQL051, for the Prophylaxis of Chemotherapy-Induced D...

                            Details : OQL051 sia first-in-disease, oral, gut-restricted CDK4/6 inhibitor – is designed to prevent the development of CID in patients receiving cytotoxic chemotherapies. The drug works by temporarily arresting the rapidly dividing intestinal mucosal cells in ...

                            Product Name : OQL051

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 06, 2023

                            Lead Product(s) : OQL051

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tryp Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Tryp Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical T...

                            Details : TRP-8802 (Oral psilocybin) in patients with Irritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with IBS.

                            Product Name : TRP-8802

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jaguar Health

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jaguar Health

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluatio...

                            Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of short bowel syndrome.

                            Product Name : Mytesi

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 08, 2023

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth